These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25801918)

  • 1. Drug-subphenotype interactions for cancer in type 2 diabetes mellitus.
    Yang X; Lee HM; Chan JC
    Nat Rev Endocrinol; 2015 Jun; 11(6):372-9. PubMed ID: 25801918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Kong AP; Xu G; Chan JC
    Diabetes Metab Res Rev; 2012 Jul; 28(5):379-87. PubMed ID: 22318884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin angiotensin system inhibitors may attenuate low LDL cholesterol-related cancer risk in type 2 diabetes.
    Yang X; Ma RC; So WY; Wang Y; Kong AP; Ozaki R; Xu G; Chan JC
    Diabetes Metab Res Rev; 2014 Jul; 30(5):415-23. PubMed ID: 24677790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Kong AP; Lee HM; Xu G; Ozaki R; Chan JC
    Acta Diabetol; 2012 Dec; 49 Suppl 1():S185-93. PubMed ID: 22722949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Kong AP; Lee HM; Yu LW; Chow CC; Ozaki R; Ko GT; Chan JC
    Diabetes Care; 2011 Feb; 34(2):375-80. PubMed ID: 20980414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of albuminuria and renal dysfunction on development of dyslipidaemia in type 2 diabetes--the Hong Kong Diabetes Registry.
    Yang X; So WY; Ma R; Ko G; Kong A; Lam C; Ho CS; Cockram C; Chow CC; Tong P; Chan J
    Nephrol Dial Transplant; 2008 Sep; 23(9):2834-40. PubMed ID: 18372388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.
    Yang X; So WY; Ma RC; Ko GT; Kong AP; Zhao H; Luk AO; Lam CW; Ho CS; Tong PC; Chan JC
    Diabetes Care; 2009 Oct; 32(10):1826-32. PubMed ID: 19592629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early-onset type 2 diabetes: higher burden of atherogenic apolipoprotein particles during statin treatment.
    Song SH; Gray TA
    QJM; 2012 Oct; 105(10):973-80. PubMed ID: 22753665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM).
    Raj R; Bhatti JS; Badada SK; Ramteke PW
    Diabetes Metab Res Rev; 2015 Oct; 31(7):663-71. PubMed ID: 25470794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry.
    Yang X; Ma RC; So WY; Yu LW; Kong AP; Ko GT; Xu G; Ozaki R; Tong PC; Chan JC
    Cancer; 2011 Feb; 117(4):862-71. PubMed ID: 20939014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes.
    Yang X; Ma RC; So WY; Ko GT; Kong AP; Zhao H; Xu G; Tong PC; Chan JC
    Diabetes Res Clin Pract; 2010 Jan; 87(1):117-25. PubMed ID: 19932519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes.
    Eliasson B; Gudbjörnsdottir S; Zethelius B; Eeg-Olofsson K; Cederholm J;
    Eur J Prev Cardiol; 2014 Nov; 21(11):1420-8. PubMed ID: 23774274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl.
    Malave H; Castro M; Burkle J; Voros S; Dayspring T; Honigberg R; Pourfarzib R
    Am J Cardiol; 2012 Sep; 110(5):662-5. PubMed ID: 22621796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.
    Bruckert E; Baccara-Dinet M; Eschwege E
    Diabet Med; 2007 Apr; 24(4):388-91. PubMed ID: 17335463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.